• Organizations: Lupin Limited
FDA grants tentative approval for Lupin's Lumify generic eye drops
Products

FDA grants tentative approval for Lupin's Lumify generic eye drops

Brimonidine tartrate ophthalmic solution, 0.025% is indicated to treat ocular redness due to minor irritations in the eye.
Lupin reports positive phase 3 program for Lucentis biosimilar
Pipeline

Lupin reports positive phase 3 program for Lucentis biosimilar

Global clinical data on LUBT010 determined clinical equivalence between the two, supporting an eventual regulatory submission for FDA approval. 
FDA approves Lupin's BromSite generic equivalent for postop inflammation and pain
Products

FDA approves Lupin's BromSite generic equivalent for postop inflammation and pain

Company is the first-to-file for generic formulation of bromfenac ophthalmic solution, 0.075%.
Lupin launches bromfenac topical generic equivalent for postop inflammation and ocular pain
Products

Lupin launches bromfenac topical generic equivalent for postop inflammation and ocular pain

Company also secures exclusive first-to-file status of bromfenac ophthalmic solution 0.007% for up to 180 days.  
FDA approves ANDA for Lupin's allergic conjunctivitis eye drop
Products

FDA approves ANDA for Lupin's allergic conjunctivitis eye drop

Generic equivalent to Bausch + Lomb’s Alrex offers a lower-cost alternative for patients.
FDA approves ANDA for Lupin's bromfenac ophthalmic solution 0.09%
Pipeline

FDA approves ANDA for Lupin's bromfenac ophthalmic solution 0.09%

Topical drug is the generic equivalent of Bausch + Lomb’s Bromday; intended to treat pain and inflammation following cataract surgery.